Found 27 results
Author Title [ Type(Desc)] Year
Filters: Author is Hill, H  [Clear All Filters]
Journal Article
F. M. Munoz, Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., and Nesin, M., Assessment of Safety in Newborns of Mothers Participating in Clinical Trials of Vaccines Administered During Pregnancy, Clin Infect Dis, vol. 59 Suppl 7, pp. S415-427, 2014.
L. M. Howard, Hoek, K. L., Goll, J. B., Samir, P., Galassie, A., Allos, T. M., Niu, X., Gordy, L. E., Creech, C. B., Prasad, N., Jensen, T. L., Hill, H., Levy, S. E., Joyce, S., Link, A. J., and Edwards, K. M., Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial, PLoS One, vol. 12, no. 1, p. e0167488, 2017.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., Creech, C. B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children, Pediatr Infect Dis J, vol. 33, pp. 865-871, 2014.
R. W. Frenck Jr, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults, Vaccine, vol. 29, no. 34, pp. 5666-5674, 2011.
R. L. Atmar, Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H., Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y., Determination of the 50% Human Infectious Dose for Norwalk Virus, J Infect Dis, vol. 209, pp. 1016-1022, 2014.
S. M. Patel, Atmar, R. L., Sahly, H. M. El, Guo, K., Hill, H., and Keitel, W. A., Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes, J Infect Dis, vol. 206, pp. 1069-1077, 2012.
D. I. Bernstein, Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K., Graham, I. L., Noah, D. L., He, F., and Hill, H., Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults, J Infec Dis, vol. 197, pp. 667-675, 2008.
N. A. Goji, Nolan, C., Hill, H., Wolff, M., Noah, D. L., Williams, T. B., Rowe, T., and Treanor, J. J., Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming with an Antigenic Variant, J Infec Dis, vol. 198, pp. 635-641, 2008.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M., Spearman, P., Rouphael, N., Jr., T. L. Rudge, Hill, H., and Goll, J. B., Immunogenicity and Safety of Four Different Dosing Regimens of Anthrax Vaccine Adsorbed for Post-Exposure Prophylaxis for Anthrax in Adults, Vaccine, vol. 32, pp. 6284-6293, 2014.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons, J Infect Dis, vol. 206, pp. 811-820, 2012.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., Creech, C. B., Hill, H., and Bellamy, A. R., Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial, JAMA, vol. 312, pp. 1420-1428, 2014.
W. H. Chen, Winokur, P. L., Edwards, K. M., Jackson, L. A., Wald, A., Walter, E. B., Noah, D. L., Wolff, M., Kotloff, K. L., Chua, J. V., Hutter, J., Stephens, I., Stapleton, J., Meier, J., Callahan, S. T., Creech, C. B., Halasa, N. B., Johnston, C., Dolor, R. J., Schmader, K. E., Woods, C. W., and Hill, H., Phase 2 Assessment of the Safety and Immunogenicity of Two Inactivated Pandemic Monovalent H1N1 Vaccines in Adults as a Component of the U.S. Pandemic Preparedness Plan in 2009, Vaccine, vol. 13, pp. 4240-4248, 2012.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5×10(8) TCID 50) of Modified Vaccinia Ankara Compared to a Standard Dose (1×10(8) TCID50) in Healthy Vaccinia-Naïve Individuals, Vaccine, vol. 32, pp. 2732-2739, 2014.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. E., Rouphael, N. G., Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, Vaccine, vol. 33, pp. 163-173, 2015.
D. F. Hoft, Xia, M., Zhang, G. L., Blazevic, A., Tennant, J., Kaplan, C., Matuschak, G., Dube, T. J., Hill, H., Schlesinger, L. S., Andersen, P. L., and Brusic, V., PO and ID BCG Vaccination in Humans Induce Distinct Mucosal and Systemic Immune Responses and CD4(+) T Cell Transcriptomal Molecular Signatures, Mucosal Immunol, vol. 11, no. 2, pp. 486-495, 2018.
D. F. Hoft, Lottenbach, K., Goll, J. B., Hill, H., Winokur, P. L., Patel, S. M., Brady, R. C., Chen, W. H., Edwards, K., Creech, C. B., Frey, S. E., Blevins, T. P., Salomon, R., and Belshe, R. B., Priming Vaccination with Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination, J Infect Dis, vol. 214, no. 7, pp. 1020-1029, 2016.
A. Galassie, Goll, J. B., Samir, P., Jensen, T. L., Hoek, K. L., Howard, L. M., Allos, T. M., Niu, X., Gordy, L. E., Creech, C. B., Hill, H., Joyce, S., Edwards, K. M., and Link, A. J., Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination., Proteomics, vol. 17, no. 12, 2017.
D. L. Noah, Hill, H., Hines, D., White, E. L., and Wolff, M. C., Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure, Clin Vaccine Immunol, vol. 16, pp. 558-566, 2009.
S. E. Frey, Bernstein, D. I., Gerber, M. A., Keyserling, H. L., Munoz, F. M., Winokur, P. L., Turley, C. B., Rupp, R. E., Hill, H., Wolff, M., Noah, D. L., Ross, A. C., Cress, G., and Belshe, R. B., Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, J Infect Dis, vol. 206, pp. 828-837, 2012.
P. L. Winokur, Patel, S. M., Brady, R., Chen, W. H., El-Kamary, S. S., Edwards, K., Creech, C. B., Frey, S., Keitel, W. A., Belshe, R., Walter, E., Bellamy, A., and Hill, H., Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine, J Infect Dis, vol. 212, no. 4, pp. 525-530, 2015.
R. C. Brady, Treanor, J. J., Atmar, R. L., Keitel, W. A., Edelman, R., Chen, W. H., Winokur, P., Belshe, R., Graham, I. L., Noah, D. L., Guo, K., and Hill, H., Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults, Vaccine, vol. 27, pp. 5091-5095, 2009.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H., Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given Without or With Aluminum Hydroxide to Healthy Adults: Results of a Phase I-II Randomized Clinical Trial, J Infec Dis, vol. 198, pp. 1309-1316, 2009.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. R., Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age, J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-224, 2015.
S. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A., Rinella, P., Hill, H., Wolff, M., Schultze, V., Han, J., Scharschmidt, B., and Belshe, R., Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults, Vaccine, vol. 28, pp. 6367-6373, 2010.